Clover Health Investments, Corp.는 메디케어 어드밴티지 보험을 전문으로 하는 미국 기반 회사입니다. 이 회사는 자체 독점 소프트웨어 플랫폼인 Clover Assistant를 활용하여 메디케어 ...
예상 EPS $-0.00 · 매출 $738.18M · 1 명의 애널리스트
예상 EPS $-0.05 · 매출 $723.47M · 1 명의 애널리스트
예상 EPS $0.05 · 매출 $2.95B · 1 명의 애널리스트
예상 EPS $0.06 · 매출 $903.44M · 1 명의 애널리스트
EPS $-0.00 · 매출 $462.33M
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $1.9B | +40.3% | -0.8% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $-85.5M | -98.9% | +2.4% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +18.5% | -30.5% | -3.3% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | -4.4% | -33.2% | +3.3% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | -4.4% | -41.7% | +3.3% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $-69.0M | -307.2% | -77.1% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | -3.6% | -247.6% | -76.9% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 0.0% | — | — |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 1.47x | -8.3% | +12.8% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $541.0M | -6.8% | +3.2% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | -0.17 vs -0.17 | +1.7% | 0.05 vs -0.00 | +2912.1% |
| 매출 서프라이즈 | $1.9B vs $1.9B | +1.1% | $743.2M vs $738.2M | +0.7% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | THORNTON JOSEPH CLAY | officer: Interim CFO | Class A Common Stock | D | 17,775 | $4.39 |
| Aug 12, 2026 | Soares Karen | officer: Chief Legal Officer | Class A Common Stock | A | 108,695 | — |
| Aug 12, 2026 | THORNTON JOSEPH CLAY | officer: Interim CFO | Class A Common Stock | A | 54,347 | — |
| Aug 10, 2026 | Toy Andrew | director, officer: Chief Executive Officer | Class A Common Stock | D | 87,798 | $4.65 |
| Jul 20, 2026 | Soares Karen | officer: Chief Legal Officer | Class A Common Stock | D | 51,700 | $4.51 |
Operator: Hello. Welcome to Clover Health's Second Quarter 2026 Earnings Call. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. Also, as a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. Ryan, you may begin. Ryan Schmidt: Good afternoon, everyone. Joining me on our call today to discuss the company's second quarter 2026 results are Andrew Toy, Clover Health's Chief Executive Officer, and Clay Thornton, the company's Interim Chief Financial Officer. You can find today's press release and the accompanying supplemental slides, as well as the company's most recent investor deck in the investor events and presentations section of our website at investors.cloverhealth.com. This webcast is being recorded and a replay will be available in the investor relations section of the Clover Health website. I'd also like to caution you that we may make forward-looking statements during today's call that are subject to risks and uncertainties, including expectations about future performance. Factors that may cause actual results to differ materially from expectations are detailed in our SEC filings, including in the risk factors section of our most recent annual report on Form 10-K and other SEC filings. Information about non-GAAP financial measures referenced, including a reconciliation of those measures to GAAP measures, can be found in the earnings materials available on our website. With that, I'll now turn the call over to Andrew. Andrew Toy: Thank you, Ryan. Thanks everyone for joining our call today. At Clover, we've always believed the greatest opportunity for AI in healthcare is not simply to make the existing system a little more efficient. It's to help physicians make better decisions for individual patients at the point of care. That's what Clover Assistant does, and our results are increasingly demonstrating that when you improve those decisions at scale, better care, membership growth, and increasing profitability can happen together. The first half of 2026 was another important proof point of this. Through the first six months of the year, we delivered market leading MA membership growth of 48%, while increasing GAAP net income by $67 million year-over-year. At the same time, total revenue in the first half increased by more than $550 million year-over-year to $1.5 billion. Consolidated gross profit increased by $104 million, and we've expanded operating leverage by more than 200 basis points as we've scaled. We believe this performance validates how our AI-powered model not only improves care for members, but also strengthens our underlying business over time. I am proud of our results so far this year and believe we are on a strong path. I want to turn now to where the business is headed. Since our last call, two things have strengthened our confidence in 2027 and …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Jamie L. Reynoso | Chief Executive Officer of Medicare Advantage | USD 1,468,166 | Female | 1969 | Active |
Andrew Toy | Co-Founder, Chief Executive Officer & Director | USD 1,319,385 | Male | 1979 | Active |
Conrad Wai | Chief Executive Officer of Counterpart Health | USD 1,211,938 | Male | 1981 | Active |
Brady Priest | Chief Executive Officer of Clover Care Services | USD 1,199,461 | Male | 1976 | Active |
Karen Soares | Chief Legal Officer, General Counsel, Senior VP & Corporate Secretary | USD 513,197 | Female | 1978 | Active |
Kumar Dharmarajan | Chief Medical Officer of Clover Assistant | — | — | 1980 | Active |
Vivek Garipalli | Co-Founder & Executive Chairman | — | Male | 1979 | Active |
Wendy Richey | Chief Compliance Officer | — | Female | — | Active |
Joseph Frank Oldakowski | VP of Finance, Controller & Principal Accounting Officer | — | Male | 1983 | Active |
Clay Thornton | Interim Chief Financial Officer | — | Male | 1990 | Active |
Rachel Fish | Chief People Officer | — | Female | — | Active |
Clover Health Investments, Corp. leverages its AI-powered Clover Assistant to drive lower claims costs and improve member profitability. Baseline and bullish DCF valuations yield fair values of $5.02 and $14.10 per share, respectively, versus the current $4.15 price. Key upside drivers include rapid membership growth, AI-enabled cost savings, and a potential $120M Medicare Advantage bonus tied to a 4.5-star CMS rating.
Clover Health Investments (CLOV) is rated Hold, with operational execution but a cautious outlook due to valuation and litigation risks. CLOV's Medicare Advantage membership grew 48% YoY, revenue and GAAP net income improved, but profitability per member lags FY2024 levels. FY2026 guidance implies negative H2 results; $120M in quality bonus revenue is at risk pending CMS litigation outcome.
Clover Health (CLOV) has delivered strong growth, profitability, and improved guidance, supporting my continued Strong Buy rating. CLOV's Medicare Advantage membership grew 48% YoY, with revenue up 56% and gross profit up 54%, driven by cohort maturation and the Clover Assistant platform. Valuation remains attractive at a 78% discount to sector median EV/sales, with upside potential if per-member profitability and SaaS revenue trends persist.
Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation.
Clover Health Investments, Corp. (CLOV) Q2 2026 Earnings Call Transcript
